| 000 | 00000cam 2200000zi 4500 |
| 001 | 9.963775 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20260928114420 |
|---|
| 006 | m o d f |
|---|
| 007 | cr cn |||||||| |
|---|
| 008 | 260622t20262026oncd o f000 0 eng d |
|---|
| 020 | |a9780662409250 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH134-47/2026E-PDF |
|---|
| 245 | 00|aMedetomidine, xylazine : |bcurrent situation in Canada. |
|---|
| 264 | 1|a[Ottawa] : |bHealth Canada = Santé Canada, |c[2026] |
|---|
| 264 | 4|c©2026 |
|---|
| 300 | |a1 online resource (1 page) : |bcharts |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |aIssued also in French under title: Médétomidine, xylazine : situation actuelle au Canada. |
|---|
| 500 | |a"Pub.: 260174." |
|---|
| 520 | |a"The aim of this info sheet is to offer key insights on medetomidine and xylazine based on samples submitted to DAS laboratories"--Purpose. |
|---|
| 650 | 0|aDrugs of abuse|zCanada|xAnalysis. |
|---|
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
|---|
| 775 | 08|tMédétomidine, xylazine : |w(CaOODSP)9.963776 |
|---|
| 856 | 40|qPDF|s605 KB|uhttps://publications.gc.ca/collections/collection_2026/sc-hc/H134-47-2026-eng.pdf |
|---|